PATH-91. Expression distribution of TEAD4 in brain tumors

Transcriptional enhancer activator domain (TEAD) family number 4 plays a significant roll in Hippo signaling pathway. The pathway regulates cell proliferation, survival, and organ size in diverse organism, and acts as a tumor suppressor. Dysregulation of Hippo signaling pathway is observed in many types of cancers. TEAD4 drives tumor metastasis and chemoresistance, and its upregulation is associated with poor prognosis in many types of cancers. Authors reported the overexpression of TEAD4 in atypical teratoid/rhabdoid tumors, which are rare embryonal brain tumor mainly occurred in early childhood and have poor prognosis. The overexpression of TEAD4 is also reported in glioblastoma and higher grade glioma, but there are no reports of other types of brain tumors. In this study, we investigated the expression distribution of TEAD4 in intraparenchymal tumors and the relationship between the level of expression and survival. Tumor samples were obtained from the patients who had received surgery and treatment in our institution. This study was approved by institutional review board (#M19-0042). There was some relationship between the level of expression and prognosis. Further studies are needed to clarify the possibility of treatment target.